Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Patients with short bowel syndrome (SBS) and distal-bowel resections lack neuroendocrine feedback regulations, potentially resulting in rapid gastrointestinal (GI) transit. The objective was to assess the efficacy of glepaglutide, a long-acting glucagon-like peptide-2 analog, on GI transit in patients with SBS.

METHODS: In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design. Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks. Endpoints were changes from baseline and included scintigraphy, wireless motility capsule (WMC, SmartPill Given Imaging, Ltd, Yokneam, Israel), and paracetamol absorption test.

RESULTS: A total of 18 patients were randomized. In the 10-mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4-50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1-80) minutes, and time to 10% small bowel-emptying of solids by 21 (1-41) minutes. The WMC transit did not significantly change in any of the dose groups. The maximum paracetamol concentration significantly increased in the 10-mg dose group; however, the area under the curve remained the same.

CONCLUSION: The prolonged GI transit after glepaglutide treatment, along with demonstrated positive effects on intestinal mucosal growth and potential effects on GI hypersecretions, is believed to contribute to the observed beneficial effects on fecal output (primary endpoint) and associated improvement in intestinal absorption.

OriginalsprogEngelsk
TidsskriftJournal of Parenteral and Enteral Nutrition
ISSN0148-6071
DOI
StatusE-pub ahead of print - 5 feb. 2020

Bibliografisk note

© 2020 American Society for Parenteral and Enteral Nutrition.

ID: 59246116